Investigations in the mouse model revealed that practical doses of PPSGG were able to sufficiently reduce IgM that binds to MAG. Doses between 1 and 10 µg were sufficient to remove between 23 and 93% of IgM anti‐MAG antibody from blood in the mouse model. Reductions in antibody were sustained for as long as 96 hr, demonstrating the pharmacologic feasibility of this highly specific therapeutic approach. In addition the investigators showed that after exposure to PPSGG, there was no activation of B cells, including human IgM anti‐MAG B cells. In addition, no activation of CD11b dendritic cells was observed. These experiments provide some assurance on the safety of this approach, if it is translated to human clinical trials. Engaging IgM targeting MAG with PPSGG appeared safe and effective in the pre‐clinical study.